Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Desentrañando las vías protectoras de los SGLT2i y GLP-1RA en la enfermedad renal diabética: papel de las proteínas adaptadoras MAP17 y D-AKAP-2 en ratones db/db y organoides renales humanos.

IP: Maria Jose Soler Romeo
Collaborators: Mario Alonso Narvaez Barros, Pamela Dominguez Baez, Vergara Arana, Ander, Sheila Bermejo Garcia, Alejandra Planas Vilaseca, Concepció Jacobs Cachá, Juan Carlos León Román
Funding agency: Instituto de Salud Carlos III
Funding: 122210
Reference: PI21/01292
Duration: 01/01/2022 - 31/12/2024

RICORS2040 - Inflamación e inmunopatología de órganos y sistemas

IP: Maria Jose Soler Romeo
Collaborators: Francesc Moreso Mateos, Oriol Bestard Matamoros, Joana Sellarés Roig, Irina Betsabe Torres Rodriguez, Concepció Jacobs Cachá, Maria Antonia Emilia Meneghini
Funding agency: Instituto de Salud Carlos III
Funding: 105765
Reference: RD21/0005/0016
Duration: 01/01/2022 - 31/12/2024

Caracterización molecular de Apolipoproteína A-Ib (ApoA-Ib): resolviendo el enigma del síndrome nefrótico idiopático.

IP: Concepció Jacobs Cachá
Collaborators: -
Funding agency: Fundación Renal Iñigo Alvarez de Toledo
Funding: 6000
Reference: FRIAT/PREMIS/2020/JACOBS
Duration: 22/09/2020 - 22/09/2020

Role of Apolipoprotein A-Ib in the idiopathic nephrotic syndrome

IP: Concepció Jacobs Cachá
Collaborators: -
Funding agency: Fundació La Marató de TV3
Funding: 199966.31
Reference: 202017/10
Duration: 30/03/2021 - 31/12/2024

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Percy Efrain Pantoja Bustillos

Percy Efrain Pantoja Bustillos

Read more
Mónica Vicente López

Mónica Vicente López

Administrative
Tenders and Procurement Unit
Finances Area
Read more
Jose  Antonio Bernabeu Garcia

Jose Antonio Bernabeu Garcia

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more
Ignasi Maspons Molins

Ignasi Maspons Molins

Research technician
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.